glp-1 australia RACGP The GLP-1 RA boom: Trends

Dismissing effective treatment because of cultural discomfort with medication is clinically indefensible

Weight loss drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) continue to have their moment in the medical space

Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies

Compounded drugs can be important for overcoming shortages or meeting unique patient needsbut compounders should not try to compound drugs in a way that circumvents FDAs approval process. The FDA claims the companies are mass marketing their GLP-1s as similar alternatives to FDA-approved drugs

-Lixisenatide is short-acting and might have limited CNS exposure, especially at standard doses

Gordon ML